| Record ID | marc_loc_2016/BooksAll.2016.part38.utf8:197850963:2465 |
| Source | Library of Congress |
| Download Link | /show-records/marc_loc_2016/BooksAll.2016.part38.utf8:197850963:2465?format=raw |
LEADER: 02465cam a2200361 a 4500
001 2011030483
003 DLC
005 20150516083128.0
008 110719s2011 enka b 001 0 eng
010 $a 2011030483
020 $a9780521766272 (hardback)
020 $a0521766273 (hardback)
035 $a(DNLM)101564947
040 $aDNLM/DLC$cDLC$dDLC
042 $apcc
050 10 $aRC377$b.M864 2011
060 10 $aWL 360
082 00 $a616.8/34$223
245 00 $aMultiple sclerosis therapeutics /$cedited by Jeffrey A. Cohen, Richard A. Rudick.
250 $a4th ed.
260 $aCambridge, UK ;$aNew York :$bCambridge University Press,$c2011.
300 $axvii, 752 p., [8] p. of col. plates :$bill. (some col.) ;$c29 cm.
490 0 $aCambridge medicine
504 $aIncludes bibliographical references and index.
505 8 $aMachine generated contents note: Part I. Introduction; Part II. Clinical Trial Methodology; Part III. Clinical Trials of Multiple Sclerosis Therapies; Part IV. Therapy in Clinical Practice.
520 $a"This book comprehensively reviews the current state of clinical trial methods in multiple sclerosis treatment, providing investigators, sponsors and specialists with current knowledge of outcome measures and study designs for disease and symptom management. The status of the rapidly evolving field of disease-modifying drugs is presented, with emphasis on the most promising therapies currently being tested. Experts discuss disease and symptom management for MS subtypes, including neuromyelitis optica and pediatric MS. In addition, key scientific advances in MS pathology, genetics, immunology and epidemiology are presented. The fourth edition has been extensively revised, featuring more than 50% new material. All chapters have been substantially updated to provide current information on rapidly evolving topics and this volume contains 15 new chapters, reflecting the growth of the field in recent years. This book is an essential reference for practitioners caring for MS patients, investigators planning or conducting clinical trials, and clinical trial sponsors"--$cProvided by publisher.
650 12 $aMultiple Sclerosis$xtherapy.
650 22 $aClinical Trials as Topic$xmethods.
650 22 $aMagnetic Resonance Imaging.
650 22 $aMultiple Sclerosis$xpathology.
650 22 $aOutcome Assessment (Health Care)
700 1 $aCohen, Jeffrey A.$q(Jeffrey Alan),$d1954-
700 1 $aRudick, Richard A.